For the year ending 2025-12-31, TXMD had $2,424K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss from continuing operations | -653 |
| Depreciation and amortization | 384 |
| Write-off and impairment of patents | 176 |
| Share-based payment compensation costs | 75 |
| Amortization of right of use assets | 809 |
| Prepaid and other current assets | -201 |
| Other assets | -2,020 |
| Accounts payable | 119 |
| Accrued expenses and other current liabilities | 272 |
| Lease liabilities | -1,078 |
| Other non-current liabilities | 129 |
| Total adjustments | 3,107 |
| Net cash provided by continuing operating activities | 2,454 |
| Net cash used in operating activities | -30 |
| Net increase in cash | 2,424 |
| Cash and cash equivalents - continuing operations, beginning of period | 5,059 |
| Total cash and cash equivalents, end of period | 7,483 |
TherapeuticsMD, Inc. (TXMD)
TherapeuticsMD, Inc. (TXMD)